Abstract
The anticardiolipin (aCL) test was first developed in the 1980s and proved to be a valuable addition to the lupus anticoagulant assay for identifying patients with a disorder that came to be later known as the antiphospholipid syndrome (APS). Although the test has relatively poor specificity for APS diagnosis, particularly at low positive levels, it has continued to play a major role in the identification and management of these patients because of its high sensitivity and ability to be measured in both serum and plasma, and despite concomitant presence of anticoagulants normally given to APS patients. In this chapter we outline the procedure for producing essential assay components and for performing the aCL ELISA, which can be used to determine the presence of IgG, IgM and IgA aCL antibodies in human samples. We also provide general guidelines that will facilitate optimal performance of the aCL ELISA assay.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, DE Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306
Harris EN, Gharavi AE, Boey ML, Patel BM, Mackworth-Young CG, Loizou S, Hughes GR (1983) Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 2(8361):1211–1214
Hu Z, Jing X, Liu J, Li M, Ye Y, Chen Y (2016) Simultaneous quantification of anticardiolipin IgG and IgM by time resolved fluoroimmunoassay. PLoS One 11(9):e0163682
Zhang S, Wu Z, Li P, Bai Y, Zhang F, Li Y (2015) Evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome. Medicine (Baltimore) 94(46):e2059
Willis R, Lakos G, Harris EN (2014) Standardization of antiphospholipid antibody testing–historical perspectives and ongoing initiatives. Semin Thromb Hemost 40(2):172–177
Merkel PA, Chang Y, Pierangeli SS, Harris EN, Polisson RP (1999) Comparison between the standard anticardiolipin antibody test and a new phospholipid test in patients with connective tissue diseases. J Rheumatol 26(3):591–596
Harris EN, Chan JK, Asherson RA, Aber VR, Gharavi AE, Hughes GR (1986) Thrombosis, recurrent fetal loss, and thrombocytopenia. Predictive value of the anticardiolipin antibody test. Arch Intern Med 146(11):2153–2156
Harris EN (1987) Syndrome of the black swan. Br J Rheumatol 26(5):324–326
Tarr T, Lakos G, Bhattoa HP, Shoenfeld Y, Szegedi G, Kiss E (2007) Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 16(1):39–45
Tektonidou MG, Laskari K, Panagiotakos DB, Moutsopoulos HM (2009) Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61(1):29–36
Reynaud Q, Lega JC, Mismetti P, Chapelle C, Wahl D, Cathebras P, Laporte S (2014) Risk of venous and arterial thrombosis according to type of antiphospholipid antibodies in adults without systemic lupus erythematosus: a systematic review and meta-analysis. Autoimmun Rev 13(6):595–608
Domingues V, Magder LS, Petri M (2016) Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE. Lupus Sci Med 3(1):e000107
Devreese KM (2012) Antiphospholipid antibodies: evaluation of the thrombotic risk. Thromb Res 130(Suppl 1):S37–S40
Tebo AE (2014) Antiphospholipid syndrome and the relevance of antibodies to negatively charged phospholipids in diagnostic evaluation. Lupus 23(12):1313–1316
Pierangeli SS, de Groot PG, Dlott J, Favaloro E, Harris EN, Lakos G, Ortel T, Meroni PL, Otomo K, Pengo V, Tincani A, Wong R, Roubey R (2011) ‘Criteria’ aPL tests: report of a task force and preconference workshop at the 13th international congress on antiphospholipid antibodies, Galveston, Texas, April 2010. Lupus 20(2):182–190
Bertolaccini ML, Amengual O, Andreoli L, Atsumi T, Chighizola CB, Forastiero R, de Groot P, Lakos G, Lambert M, Meroni P, Ortel TL, Petri M, Rahman A, Roubey R, Sciascia S, Snyder M, Tebo AE, Tincani A, Willis R (2014) 14th international congress on antiphospholipid antibodies task force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 13(9):917–930
Pierangeli SS, Harris EN (2008) A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 3(5):840–848
Lakos G, Favaloro EJ, Harris EN, Meroni PL, Tincani A, Wong RC, Pierangeli SS (2012) International consensus guidelines on anticardiolipin and anti-beta2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies. Arthritis Rheum 64(1):1–10
Devreese KM, Pierangeli SS, de Laat B, Tripodi A, Atsumi T, Ortel TL (2014) Testing for antiphospholipid antibodies with solid phase assays: guidance from the SSC of the ISTH. J Thromb Haemost 12(5):792–795
Harris EN (1990) Special report. The second international anti-cardiolipin Standardization Workshop/the Kingston Anti-phospholipid Antibody Study (KAPS) group. Am J Clin Pathol 94(4):476–484
Ichikawa K, Tsutsumi A, Atsumi T, Matsuura E, Kobayashi S, Hughes GR, Khamashta MA, Koike T (1999) A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2-glycoprotein I-dependent anticardiolipin and anti-beta2-glycoprotein I antibodies. Arthritis Rheum 42(11):2461–2470
Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1(8476):307–310
CLSI (2013) Measurement procedure comparison and bias estimation using patient samples; approved guideline, 3rd edn. CLSI document EP09-A3. Clinical and Laboratory Standards Institute, Wayne, PA
CLSI (2008) Collection, transport, and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline, 5th edn. CLSI document H21-A5. Clinical and Laboratory Standards Institute, Wayne, PA
Pierangeli SGR, Harris EN (1989) Determination of the calibration equation which achieved best accuracy and precision of the anticardiolipin assay. Arthritis Rheum 32:S123
CLSI (2008) Defining, establishing, and verifying reference intervals in the clinical laboratory; approved guideline, 3rd edn. CLSI document EP28-A3c. Clinical and Laboratory Standards Institute, Wayne, PA
Ruffatti A, Salvan E, Del Ross T, Gerosa M, Andreoli L, Maina A, Alijotas-Reig J, De Carolis S, Mekinian A, Bertero MT, Canti V, Brucato A, Bremme K, Ramoni V, Mosca M, Di Poi E, Caramaschi P, Galeazzi M, Tincani A, Trespidi L (2014) Treatment strategies and pregnancy outcomes in antiphospholipid syndrome patients with thrombosis and triple antiphospholipid positivity. A European multicentre retrospective study. Thromb Haemost 112(4):727–735
Yelnik CM, Urbanski G, Drumez E, Sobanski V, Maillard H, Lanteri A, Morell-Dubois S, Caron C, Dubucquoi S, Launay D, Duhamel A, Hachulla E, Hatron PY, Lambert M (2016) Persistent triple antiphospholipid antibody positivity as a strong risk factor of first thrombosis, in a long-term follow-up study of patients without history of thrombosis or obstetrical morbidity. Lupus 26(2):163–169
Forastiero R (2014) Multiple antiphospholipid antibodies positivity and antiphospholipid syndrome criteria re-evaluation. Lupus 23(12):1252–1254
CLSI (2005) Interference testing in clinical chemistry; approved guideline, 2nd edn. CLSI document EP07-A2. Clinical and Laboratory Standards Institute, Wayne, PA
Cabral AR, Cabiedes J, Alarcon-Segovia D (1994) Tween 20 detaches cardiolipin from ELISA plates and makes anticardiolipin antibodies undetectable regardless of the presence of beta 2-glycoprotein-I. J Immunol Methods 175(1):107–114
Sammaritano LR, Lockshin MD, Gharavi AE (1992) Antiphospholipid antibodies differ in aPL cofactor requirement. Lupus 1(2):83–90
Chamley LW, Pattison NS, McKay EJ (1991) Anomalous anticardiolipin antibody results may be due to cofactor variability. Am J Hematol 37(4):289
Pierangeli SS, Favaloro EJ, Lakos G, Meroni PL, Tincani A, Wong RC, Harris EN (2012) Standards and reference materials for the anticardiolipin and anti-beta2glycoprotein I assays: a report of recommendations from the APL task force at the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta 413(1–2):358–360
Schlame M, Haller I, Sammaritano LR, Blanck TJ (2001) Effect of cardiolipin oxidation on solid-phase immunoassay for antiphospholipid antibodies. Thromb Haemost 86(6):1475–1482
Lockshin MD, Qamar T, Levy RA, Best MP (1988) IgG but not IgM anti-phospholipid antibody binding is temperature dependent. J Clin Immunol 8(3):188–192
Ruffatti A, Olivieri S, Tonello M, Bortolati M, Bison E, Salvan E, Facchinetti M, Pengo V (2008) Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 6(10):1693–1696
Acknowledgement
RW is supported by a Mallinckrodt-Questcor Fellowship Grant and both RW and EP are supported by an NIH Grant R01 AR056745-01A1.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer Science+Business Media LLC
About this protocol
Cite this protocol
Willis, R., Papalardo, E., Nigel Harris, E. (2017). Solid Phase Immunoassay for the Detection of Anticardiolipin Antibodies. In: Favaloro, E., Lippi, G. (eds) Hemostasis and Thrombosis. Methods in Molecular Biology, vol 1646. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-7196-1_16
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7196-1_16
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-7194-7
Online ISBN: 978-1-4939-7196-1
eBook Packages: Springer Protocols